On October 5, 2026, molecular oncology specialists highlighted Lynparza® (Olaparib 150 mg and 100 mg film-coated tablets) developed by AstraZeneca and MSD as the global benchmark poly (ADP-ribose) polymerase (PARP) inhibitor. By exploiting homologous recombination repair deficiency (HRD) through synthetic lethality, Lynparza provides sustained survival benefits across BRCA-mutated advanced ovarian, germline BRCA-mutated HER2-negative metastatic breast cancer, metastatic pancreatic adenocarcinoma, and mCRPC.

Through Onco Medicine, verified original manufacturer packs of Lynparza Olaparib 150mg & 100mg Tablets are supplied to hospital oncology departments, practicing oncologists, and named patients globally via GDP-certified delivery with full Certificate of Analysis (COA) batch release.

Molecular Biology: PARP Trapping & Synthetic Lethality

Lynparza acts via targeted exploitation of DNA repair defects in tumor cells:

• Single-Strand DNA Repair Inhibition: PARP enzymes (specifically PARP1 and PARP2) play an indispensable role in cellular base excision repair (BER). Lynparza binds to the catalytic site of PARP and traps the enzyme at sites of single-strand DNA breaks, preventing repair progression.
• Replication Fork Collapse: When DNA replication machinery encounters trapped PARP-DNA complexes, stalled replication forks collapse, creating lethal double-strand breaks (DSBs).
• Selective Synthetic Lethality: Normal cells repair DSBs efficiently through homologous recombination repair (HRR). In contrast, tumor cells harboring deleterious BRCA1, BRCA2, or other HRR pathway mutations cannot repair DSBs accurately, causing catastrophic genomic instability and selective apoptosis of cancer cells while sparing non-malignant tissue.

Landmark Clinical Trial Outcomes Across Multiple Indications

Extensive Phase 3 clinical trials have proven Lynparza's transformative efficacy:

• SOLO-1 (Advanced Ovarian Cancer): First-line maintenance therapy in newly diagnosed BRCA-mutated advanced ovarian cancer resulted in a 67% reduction in risk of disease progression or death, with unprecedented 7-year overall survival plateaus.
• OlympiA (Early-Stage Breast Cancer): Adjuvant treatment for 1 year in patients with high-risk, germline BRCA-mutated HER2-negative early breast cancer significantly improved invasive disease-free survival (IDFS) and overall survival.
• PROfound (Metastatic Castration-Resistant Prostate Cancer): In men with HRR gene alterations who had progressed on enzalutamide or abiraterone, Lynparza significantly extended overall survival over physician's choice of alternative hormonal therapy.
• POLO (Metastatic Pancreatic Cancer): Demonstrated significant prolongation of progression-free survival in patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease had not progressed during platinum-based chemotherapy.

Clinical Dosing Guidelines & Hematologic Safety Surveillance

Safe and effective oral PARP inhibitor therapy requires careful clinical oversight:

• Recommended Dosage: Standard dose is 300 mg orally twice daily (two 150 mg tablets taken approximately 12 hours apart), with or without food. Tablets must be swallowed whole and not chewed, crushed, or dissolved.
• Renal Dose Adjustments: In patients with moderate renal impairment (creatinine clearance 31–50 mL/min), the recommended dose is reduced to 200 mg orally twice daily (two 100 mg tablets twice daily).
• Hematologic Toxicity Monitoring: Baseline complete blood count (CBC) must be obtained prior to initiation, followed by monthly CBC monitoring. Anemia, neutropenia, and thrombocytopenia are managed with dose interruptions or stepwise decrements to 250 mg or 200 mg twice daily. Persistent cytopenias warrant bone marrow biopsy to rule out myelodysplastic syndrome (MDS) / acute myeloid leukemia (AML).

Global Named-Patient Sourcing via Onco Medicine

For international patients navigating domestic formulary delays or supply shortages, Onco Medicine ensures prompt cross-border procurement of genuine AstraZeneca Lynparza:

• Official Regulatory Import Pathways: Managed under US FDA Personal Importation Policy (PIP), UK MHRA Named-Patient Import, Australian TGA Special Access Scheme (SAS), Brazilian ANVISA RDC authorizations, and UAE MOHAP import regulations.
• Complete Batch Traceability: Provided exclusively in tamper-evident manufacturer cartons accompanied by official batch release certificates and cold-chain compliance.
• Express Global Transit: Dispatched with expedited couriers reaching oncology clinics and home delivery within 4 to 8 business days worldwide.

Contact our molecular oncology desk for availability, pricing, and import documentation: support@onco-medicine.com or connect with our pharmacists on WhatsApp (+91 94275 19809).